Dr Lal Pathlabs Ltd (LALPATHLAB)
₹1,899.90
Mkt cap
₹31,923 Cr
P/E ratio
56.80
P/B
12.67
Div yield
0.74%
ROE
22.30%
ROCE
28.00%
EPS (TTM)
₹33.45
Book value
₹150
52W range
1,308–1,968
Sector
Healthcare
Price history
Previous close
Dr. Lal PathLabs Limited is one of India’s leading consumer healthcare brand in diagnostic services. It has an integrated nationwide network, where patients and healthcare providers are offered a broad range of diagnostic and related healthcare tests and services for use in: core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. The services of DLPL are aimed at individual patients, hospitals and other healthcare providers and corporates. [1]
NSE LALPATHLABBSE 539524
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−3.48% from high₹1,900
₹1,308+45.30% from low₹1,968
Current
₹1,899.90
Prev close
₹1,900.00
Day
−0.01%
Price performance
1D
−0.01%
1W
−0.24%
1M
−2.77%
3M
+21.11%
6M
+41.87%
1Y
+17.70%
YTD
+28.88%
Financials
Revenue, profit & margin
P/E ratio
56.8×
LALPATHLAB is 34% above the sector median of 42.4×
LALPATHLAB56.8×
Sector median42.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 541 | 601 | 539 | 545 | 602 | 660 | 597 | 603 | 670 | 731 | 660 | 703 | 798 | |
| Expenses | 395 | 424 | 398 | 401 | 432 | 458 | 443 | 434 | 478 | 506 | 480 | 516 | 550 | |
| Operating Profit | 146 | 178 | 141 | 145 | 170 | 202 | 154 | 169 | 192 | 224 | 179 | 187 | 248 | |
| OPM % | 27% | 30% | 26% | 27% | 28% | 31% | 26% | 28% | 29% | 31% | 27% | 27% | 31% | |
| Other Income | 14 | 18 | 18 | 18 | 21 | 22 | 25 | 26 | 28 | 25 | -6 | 24 | 32 | |
| Interest | 8 | 8 | 7 | 7 | 6 | 6 | 5 | 5 | 5 | 5 | 7 | 6 | 6 | |
| Depreciation | 35 | 36 | 36 | 37 | 35 | 35 | 36 | 36 | 35 | 40 | 42 | 45 | 44 | |
| Profit before tax | 118 | 152 | 116 | 120 | 150 | 183 | 138 | 153 | 181 | 204 | 124 | 160 | 229 | |
| Tax % | 29% | 27% | 29% | 28% | 28% | 29% | 29% | -1% | 26% | 25% | 26% | 17% | 25% | |
| Net Profit | 84 | 111 | 82 | 86 | 108 | 131 | 98 | 156 | 134 | 152 | 91 | 132 | 170 | |
| EPS in Rs | 4.95 | 6.55 | 4.87 | 5.06 | 6.37 | 7.73 | 5.78 | 9.26 | 7.90 | 8.99 | 5.40 | 7.84 | 10.11 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.27% · closed higher next day 20 of last 39
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 2 Nov '23◦ | 1 Feb '24◦ | 10 May '24◦ | 7 Aug '24◦ | 23 Oct '24◦ | 30 Jan '25◦ | 25 Apr '25◦ | 31 Jul '25 | 31 Oct '25 | 30 Jan '26 | 30 Apr '26 | 24 Jul '26 |
| Earnings day | +5.34% | −1.85% | +6.24% | −2.69% | −6.35% | −0.86% | −3.42% | +1.67% | +1.49% | +1.02% | −2.19% | +4.27% |
| +1 day | +7.46% | −3.13% | +6.12% | −1.92% | −3.63% | −0.57% | −4.58% | +2.52% | +5.36% | +1.61% | +12.56% | +8.30% |
| +5 days | +8.68% | −1.91% | +8.00% | +0.80% | −4.38% | −2.51% | −3.55% | +3.68% | 0.00% | +3.45% | +18.03% | +12.93% |
| +15 days | +7.49% | −2.06% | +13.90% | +4.36% | −8.84% | −8.77% | −3.09% | +8.90% | +1.03% | +0.51% | +16.62% | +13.59% |
| +30 days | +2.84% | −19.53% | +15.80% | +0.53% | −2.75% | −11.63% | +1.68% | +6.42% | −7.45% | −3.88% | +15.61% | +11.29% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 4 Per Share | 4.00 | 25 Jun '26 | 26 Jun '26 |
Shareholding
as of Jun 202653.19%Promoter
Promoters53.19%0.02
FIIs17.35%0.17
DIIs21.59%0.22
Public7.48%0.40
Government0.01%
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| LALPATHLAB | ₹1,901.90 | 56.78 | 31,923 | 0.74% | 171 | +28.02% | 798 | +19.10% | 28.00% |
| VIJAYA | ₹1,497.50 | 82.27 | 15,424 | 0.13% | 53 | +37.60% | 231 | +22.83% | 20.53% |
| METROPOLIS | ₹577.75 | 57.56 | 11,982 | 0.35% | 57 | +25.77% | 450 | +16.62% | 17.81% |
| THYROCARE | ₹573.15 | 50.47 | 9,123 | 1.63% | 51 | +34.06% | 240 | +24.34% | 35.38% |
| NEPHROPLUS | ₹710.85 | 83.99 | 7,148 | 0.00% | 32 | +34.89% | 282 | +23.69% | 15.34% |
| KRSNAA | ₹564.05 | 18.49 | 1,830 | 0.35% | 16 | −19.12% | 211 | +19.95% | 12.70% |
| SURAKSHA | ₹338.90 | 49.30 | 1,765 | 0.15% | 13 | +38.40% | 88 | +20.75% | 17.29% |
| Median: 15 Co. | ₹522.00 | 42.38 | 1,306 | 0.13% | 14 | +28.77% | 157 | +19.52% | 23.07% |
Filings
Annual reports11
Concall transcripts124
TranscriptJul 2026PPTJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025TranscriptOct 2024PPTOct 2024TranscriptAug 2024PPTAug 2024TranscriptMay 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 SepAnnouncement under Regulation 30 (LODR)-Updates on Acquisition 27 Aug - Dr. Lal Ventures completed 30% stake subscription in Neuome Technologies on August 27, 2026; Neuome became associate.Incorporation Of A Step-Down Subsidiary Company 19 Aug - Dr Lal PathLabs incorporated Dr Lal PathLabs Indomed LLC in Tashkent, Uzbekistan; 70% stake subscribed.Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 6 AugAnnouncement under Regulation 30 (LODR)-Earnings Call Transcript 30 Jul